Advancing the promises of precision medicine for patients with gastrointestinal stromal tumor | Zendy

Joaquina Baranda | Zendy; Andrew K. Godwin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Advancing the promises of precision medicine for patients with gastrointestinal stromal tumor

Author(s) -

Joaquina Baranda,

Andrew K. Godwin

Publication year - 2019

Publication title -

gastrointestinal stromal tumor

Language(s) - English

Resource type - Journals

ISSN - 2663-1911

DOI - 10.21037/gist.2019.10.01

Subject(s) - gist , stromal tumor , malignancy , gastrointestinal tract , medicine , gastrointestinal cancer , precision medicine , cancer , stromal cell , oncogene , cancer medicine , mesenchymal stem cell , oncology , pathology , colorectal cancer , cell cycle

Gastrointestinal stromal tumor (GIST) treatment is one of the best examples of how precision medicine can impact outcomes in patients with cancer. In 1998, Hirota and colleagues reported that GISTs carried gain-of-function mutations in the proto-oncogene, c-KIT (1). Although considered a rare malignancy, GIST is the most common mesenchymal neoplasm of the gastrointestinal tract (2-4).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research